Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Urological Oncology: New Insights into Diagnosis and Treatment
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Urological Oncology: New Insights into Diagnosis and Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 30 May 2025 | Viewed by 5440

Special Issue Editor

Dr. Aldo Brassetti

E-Mail Website
Guest Editor
Department of Oncologic Urology, IRCCS “Regina Elena” National Cancer Institute of Rome, Rome, Italy
Interests: robotic surgical procedures; prostate cancer; urinary bladder neoplasms; penile neoplasms; learning curve; urinary diversion

Special Issue Information

Dear Colleagues,

Urological oncology is a constantly evolving field. Each year brings forward new insights into diagnostic methods and treatment approaches, encompassing surgical techniques, chemotherapy, immunotherapy, and radiotherapeutic strategies, which significantly influence clinical practice and shape guideline recommendations.

The scope of these innovations is consistently focused on maximizing benefits related to oncological outcomes, including overall survival, recurrence-free survival, quality of life, functional outcomes, among others. Precision in diagnostic methods is continually improving, as seen in techniques such as MRI–ultrasound prostate fusion biopsy, MRI in muscle-invasive cancer, and prostate cancer diagnosis. Surgical techniques have made significant progress over the past decade, with a focus on minimally invasive procedures that seek to achieve precise treatment while preserving function; examples include ultrapreservative radical prostatectomy, totally clampless partial nephrectomy, and totally intracorporeal urinary diversions and neobladders. Regarding medical and radiological therapies, new strategies are constantly emerging and being studied with regard to neoadjuvant or adjuvant therapy indications, with dose adjustments to achieve disease control and reduce side-effects.

Urologic oncology is a comprehensive field, requiring interdisciplinary cooperation with the primary goal of enhancing both quality of life and disease control. This Special Issue is dedicated to publishing contributions centered around innovative strategies in the diagnosis and treatment of urinary tumors, contributing to the growing body of evidence in the field.

Dr. Aldo Brassetti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • minimally invasive surgical procedures
  • robotic surgical procedures
  • laparoscopy
  • augmented reality
  • prostatectomy
  • nephrectomy
  • cystectomy
  • diagnosis
  • immunotherapy
  • chemotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1039 KiB  
Article
The Effect of Surgical Resection on Cancer-Specific Mortality in Pelvic Soft Tissue Sarcoma According to Histologic Subtype and Stage
by Mattia Luca Piccinelli, Andrea Baudo, Stefano Tappero, Cristina Cano Garcia, Francesco Barletta, Reha-Baris Incesu, Simone Morra, Lukas Scheipner, Zhe Tian, Stefano Luzzago, Francesco Alessandro Mistretta, Matteo Ferro, Fred Saad, Shahrokh F. Shariat, Sascha Ahyai, Nicola Longo, Derya Tilki, Alberto Briganti, Felix K. H. Chun, Carlo Terrone, Luca Carmignani, Ottavio de Cobelli, Gennaro Musi and Pierre I. Karakiewiczadd Show full author list remove Hide full author list
J. Clin. Med. 2024, 13(19), 5787; https://doi.org/10.3390/jcm13195787 - 28 Sep 2024
Viewed by 960
Abstract
Background/Objectives: The impact of surgical resection versus non-resection on cancer-specific mortality (CSM) in soft tissue pelvic sarcoma remains largely unclear, particularly when considering histologic subtypes such as liposarcoma, leiomyosarcoma, and sarcoma NOS. The objective of the present study was to first report [...] Read more.
Background/Objectives: The impact of surgical resection versus non-resection on cancer-specific mortality (CSM) in soft tissue pelvic sarcoma remains largely unclear, particularly when considering histologic subtypes such as liposarcoma, leiomyosarcoma, and sarcoma NOS. The objective of the present study was to first report data regarding the association between surgical resection status and CSM in soft tissue pelvic sarcoma. Methods: Using data from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2019, we identified 2491 patients diagnosed with pelvic soft tissue sarcoma. Cumulative incidence plots were used to illustrate CSM and other-cause mortality rates based on the histologic subtype and surgical resection status. Competing risk regression models were employed to assess whether surgical resection was an independent predictor of CSM in both non-metastatic and metastatic patients. Results: Among the 2491 patients with soft tissue pelvic sarcoma, liposarcoma was the most common subtype (41%), followed by leiomyosarcoma (39%) and sarcoma NOS (20%). Surgical resection rates were 92% for liposarcoma, 91% for leiomyosarcoma, and 58% for sarcoma NOS in non-metastatic patients, while for metastatic patients, the rates were 55%, 49%, and 23%, respectively. In non-metastatic patients who underwent surgical resection, five-year CSM rates by histologic subtype were 10% for liposarcoma, 32% for leiomyosarcoma, and 27% for sarcoma NOS. The multivariable competing risk regression analysis showed that surgical resection provided a protective effect across all histologic subtypes in non-metastatic patients (liposarcoma HR: 0.2, leiomyosarcoma HR: 0.5, sarcoma NOS HR: 0.4). In metastatic patients, surgical resection had a protective effect for those with leiomyosarcoma (HR: 0.6) but not for those with sarcoma NOS. An analysis for metastatic liposarcoma was not possible due to insufficient data. Conclusions: In non-metastatic soft tissue pelvic sarcoma, surgical resection may be linked to a reduction in CSM. However, in metastatic patients, this protective effect appears to be limited primarily to those with leiomyosarcoma. Full article
(This article belongs to the Special Issue Urological Oncology: New Insights into Diagnosis and Treatment)
►▼ Show Figures

Figure 1

13 pages, 760 KiB  
Article
Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma
by Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai, Kengo Kawase, Yoshihisa Mimura, Yosuke Sugiyama, Atsushi Okada, Yoko Furukawa-Hibi and Takahiro Yasui
J. Clin. Med. 2024, 13(12), 3365; https://doi.org/10.3390/jcm13123365 - 7 Jun 2024
Cited by 2 | Viewed by 2194
Abstract
Background/Objectives: Immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) combination therapy is an essential first-line therapy for advanced renal cell carcinoma (RCC). However, reports of its efficacy and safety as late-line therapy are lacking. This study aimed to examine the efficacy and safety of IO+TKI [...] Read more.
Background/Objectives: Immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) combination therapy is an essential first-line therapy for advanced renal cell carcinoma (RCC). However, reports of its efficacy and safety as late-line therapy are lacking. This study aimed to examine the efficacy and safety of IO+TKI combination therapy as a late-line therapy for patients with RCC. Methods: We retrospectively examined 17 patients with RCC who received IO+TKI combination therapy as a second-line therapy or beyond (pembrolizumab plus axitinib, n = 10; avelumab plus axitinib, n = 5; nivolumab plus cabozantinib, n = 2). Results: The overall response and disease control rates of IO+TKI combination therapy were 29.4% and 64.7%, respectively. The median overall survival was not attained. Progression-free survival was 552 days, and 94.1% of patients (n = 16) experienced adverse effects (AEs) of any grade; moreover, 41.2% of patients (n = 7) experienced grade ≥ 3 immuno-related AEs. Conclusions: IO+TKI combination therapy may be a late-line therapy option for RCC. Full article
(This article belongs to the Special Issue Urological Oncology: New Insights into Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 275 KiB  
Review
Insights into the Interplay between the Urinary Microbiome and Bladder Cancer: A Comprehensive Review
by Rigoberto Pallares-Mendez, Aldo Brassetti, Alfredo Maria Bove and Giuseppe Simone
J. Clin. Med. 2024, 13(16), 4927; https://doi.org/10.3390/jcm13164927 - 21 Aug 2024
Cited by 1 | Viewed by 1788
Abstract
New insights in the urinary microbiome have led to a better understanding being built of the shifts in bacterial representations from health to disease; these hold promise as markers for diagnosis and therapeutic responses. Although several efforts have been made to identify a [...] Read more.
New insights in the urinary microbiome have led to a better understanding being built of the shifts in bacterial representations from health to disease; these hold promise as markers for diagnosis and therapeutic responses. Although several efforts have been made to identify a “core urinary microbiome”, different fingerprints have been identified in men and women that shift with age. The main bacterial groups overall include Firmicutes, Actinobacteria, Fusobacteria, and Bacteroidetes. Although patients with bladder cancer have a microbiome that is similar to that of healthy individuals, differences have been observed at the species level with Fusobacterium nucleatum and Ralstonia, and at the genus level with Cutibacterium. Different bacterial representations may influence extracellular matrix composition, affecting tumor metastatic spreading and tumorigenic metalloproteinase expression. Furthermore, gene expression affecting targets of immune therapy, such as PD-L1, has been associated with changes in bacterial representations and therapeutic response to BCG. This comprehensive review aims to examine the influence of the urinary microbiome in bladder cancer. Full article
(This article belongs to the Special Issue Urological Oncology: New Insights into Diagnosis and Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop